logo

For the Inventor, By the Inventor

Iowa City, IA, United States of America

Ronald D Schoenwald

This inventor holds 28 USPTO granted patents, primarily in Ophthalmic Treatments. Top assignees: University of Iowa Research Foundation, Angelini Pharmaceuticals. Active years: 1984-1999.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ronald D Schoenwald. Retrieved from https://idiyas.com/inventor/ronald-d-schoenwald

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28

% Patents Active = 100.0

Average Co-Inventor Count = 1.9

ph-index = 8

Forward Citations = 233(Granted Patents)


Company Filing History:

goldMedal26 out of 925 
 
University of Iowa Research Foundation
 patents
silverMedal2 out of 4 
 
Angelini Pharmaceuticals
 patents

Years Active: 1984-1999

Loading Chart...
Areas of Expertise:
Glaucoma Treatment
Ocular Protein Stimulants
Ethyl Ethacrynate
Sigma Receptor Ligands
Carbonic Anhydrase Inhibitors
Topical Ophthalmic
Mydriatic Agents
Lacrimal Secretion Stimulant
Controlled Release Gel
Anti-Inflammatory
Prodrugs
28 patents (USPTO):Explore Patents
1. 5961987 - Ocular protein stimulants (1999-10-05),
2. 5776482 - Tetrahydroquinoline analogues for use in glaucoma treatment (1998-07-07),
3. 5654335 - Topical use of ethyl ethacrynate for glaucoma treatment (1997-08-05),
4. 5565434 - Hexose and pentose prodrugs of ethacrynic acid (1996-10-15),
5. 5387614 - Use of sigma receptor ligands as salivary gland stimulants (1995-02-07),
6. 5382576 - 1-aza-1-arylcycloalkanes as topical glaucoma treatment agents (1995-01-17),
7. 5322859 - Antiglaucoma drug composition and method (1994-06-21),
8. 5256698 - Treatment of psychosis using cyclohexyl-phenyl-lower alkyl amine (1993-10-26),
9. 5225424 - Methazolamide-derived carbonic anhydrase inhibitors (1993-07-06),
10. 5179124 - Anti-inflammatory for use in external and internal eye inflammations (1993-01-12),
11. 5157044 - Analogs of carbonic anhydrase inhibitors and their use as topical IOP (1992-10-20),
12. 5104887 - Topical ophthalmic imino substituted (1992-04-14),
13. 5095026 - Prodrugs of carbonic anhydrase inhibitors (1992-03-10),
14. 4975449 - Topical treatment of glaucoma with 2-benzothiazolesulfonamide derivative (1990-12-04),
15. 4975448 - 6-amino-2-benzothiazolesulfonamide and topical treatment compositions (1990-12-04),

Title: Ronald D. Schoenwald: A Pioneer in Ocular Therapeutics

Introduction

Ronald D. Schoenwald, based in Iowa City, IA, has made significant contributions to the field of ocular therapeutics with a remarkable portfolio of 28 patents. His work primarily focuses on innovative treatment methods aimed at improving eye health, particularly in the areas of tear production and glaucoma management.

Latest Patents

Among his latest innovations, Schoenwald has developed ocular protein stimulants designed to enhance tear production. This includes formulations of reduced basicity prepared from cyclopropyl adducts of tertiary amines. Additionally, he has created tetrahydroquinoline analogues intended for the treatment of glaucoma, which effectively reduce intraocular eye pressure through topically administered compositions.

Career Highlights

Throughout his career, Ronald D. Schoenwald has worked with esteemed institutions, notably the University of Iowa Research Foundation, where he contributed to cutting-edge research in ocular medications. His association with Angelini Pharmaceuticals further underscores his dedication to advancing eye care.

Collaborations

Schoenwald has collaborated with notable colleagues in his field, including Charles F. Barfknecht and Du-Shieng Chien. Their collective expertise has undoubtedly enriched the research and development processes in ocular therapeutics.

Conclusion

Ronald D. Schoenwald stands out as an influential figure in the realm of ocular science. His pioneering patents and collaborations demonstrate his commitment to enhancing eye health and his drive for innovation continues to inspire future advancements in medical treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…